MGC has an ambitious international research and development agenda, supported by our scientific board and global relationships with high profile research institutions. MGC’s research and development projects include preclinical, clinical, botanical development and novel drug delivery systems, focused at the intersection of plant-derived medicines and the pharmaceutical industry.
The Company’s Clinical Advisory Team is responsible for leading the company’s development in three main areas of focus: Neurology, Oncology and Autoimmune.
Currently MGC’s research and development efforts and clinical trials are centered in Slovenia, Australia, Israel and India.
MGC has entered into an exclusive research agreement with RMIT, one of Australia’s leading universities. Pursuant to the agreement, the Company and RMIT have co-funded the construction of a state of the art research facility, where several avenues of research are currently being pursued, including:
Development of drug delivery systems for cannabinoid based products for cancer using nanotechnology targeting the CB2 receptors to control angiogenesis and inflammation.
Nanotechnology based drug delivery
Harnessing the nanotechnology based drug deliver experience of RMIT and The Hebrew University to develop delivery of cannabinoid formulations.
Combination of traditional medicine and cannabinoid therapies
Leverage to knowledge of traditional medicine and its research at RMIT to create new therapeutics by combing multiple compounds and exploring how they work together.
National Institute of Biology, Slovenia
MGC, in conjunction with NIB, has recently published data following successful preclinical research assessing the efficacy of phytocannabinoid-derived medicines on glioblastoma. This study is a long term, in vitro study with significant potential to create treatments for a currently untreatable indication.
Ongoing breeding project between the Biotechnical Faculty of the University of Ljubljana and MGC Pharmaceuticals.
MGC Pharmaceuticals genotypes were grown, flowered and harvested in the Faculties facilities and are undergoing EU registration:
MX-THC-10/3 37.83 THC 0.06 CBD
MXC-THC-81/5 0.70 THC 21.24 CBD
MXC-THC-40/3 29.46 THC 0.12 CBD
MXC-THC-40/2 14.56 THC 14.25 CBD